CTIS2023-503753-35-01进行中（未招募）1 期
FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity - FIT-HF trial
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial, Age>18 years at the time of inclusion, Body mass index (BMI) = 30 kg/m2, Have heart failure with reduced ejection fraction (EF<=40%) established by: a.echocardiography b.cardiac magnetic resonance, Being on stable optimal-medical-heart failure treatment for 4 weeks.
排除标准
- •Cardiovascular-related: 1.Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening 2.Planned coronary, carotid or peripheral artery revascularisation known on the day of screening 3.Presently classified as being in New York Heart Association (NYHA) Class IV heart failure 4.Transient tachycardic induced heart failure, Glycaemia-related: 5.History of type 1 diabetes 6.Treatment with any GLP-1 RA within 90 days before screening 7.Type 2 diabetes and treatment other than metformin or SGLT-2 inhibitor, General safety: 8.History or presence of chronic pancreatitis 9.Presence of acute pancreatitis within the past 180 days prior to the day of screening 10.Kidney disease with eGFR<35ml/min 11.Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed 12.Severe psychiatric disorder which in the investigator’s opinion could compromise compliance with the protocol 13.Known or suspected hypersensitivity to trial product(s) or related products 14.Previous participation in this trial. Participation is defined as randomisation 15.Receipt of any investigational medicinal product within 30 days before screening 16.Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method 17.Any disorder, unwillingness or inability, which in the investigator’s opinion, might jeopardise the subject’s safety or compliance with the protocol
研究者
相似试验
招募中
2 期
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart FailureHeart Failure With Reduced Ejection FractionObesityWeight LossChronic Heart FailureNCT06423599Jens D Hove, MD,PHD100
已完成
2 期
Effects of rapid or slow weight loss on body composition and metabolic risk factorsobesity.Dietary counselling and surveillanceIRCT2016010424699N2Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences68
招募中
不适用
Effect of weight status and different weight-loss methods on gut-brain interactionsObesitascorpulencemorbidly overweight10003018obesityNL-OMON43908niversiteit Maastricht45
招募中
不适用
The effect of weight loss on the quality of life and balance of obese patients who underwent stomach reduction surgeryObesityRBR-7tvv57niversidade Federal de São Paulo
已完成
不适用
Suppression effects on body weight and fat of calcium alginate in healthy adultsmetabolic syndromeJPRN-UMIN000019658Takasaki University of Health and Welfare10